In this regard, the activation of Nrf2 signaling is considered as one of the most important signaling pathways that is targeted by therapeutic strategies for reducing OS in patients with polycystic ovary syndrome [85]. This evidence concerns the gene NFE2L2 and polycystic ovary syndrome.